BridgeBio Pharma Inc. held its 2025 Annual Meeting of Stockholders on June 20, 2025. Stockholders approved several proposals, including an amendment to the Certificate of Incorporation to limit the liability of certain officers, the amendment and restatement of the 2021 Stock Option and Incentive Plan to increase the number of shares reserved for issuance, and the election of five director nominees to the Board. Additionally, the adjournment of the Annual Meeting was approved in case there were insufficient votes for any proposals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.